5-Fu联用MMC的体外药敏及其对大肠癌疗效相关性研究

目的: 探讨5-Fu联用MMC治疗大肠癌的体外药敏性及与临床化疗疗效的相关性.方法: 用MTT法测定联合化疗方案5-Fu MMC对96例Dukes B,C期大肠癌的体外敏感性,统计其协同、相加、拮抗作用的发生率,用双盲法调查临床联用5-Fu和MMC 治疗大肠癌的疗效,统计术后3 a复发率.结果: 88例大肠癌中联合用药方案体外检测结果存在拮抗、相加、协同作用.42例联合用药中,有15例体外检测结果发生拮抗作用,其中8例3 a内复发;有27例体外检测结果发生协同、相加作用,其中仅有5例3 a内复发,前者复发率大于后者,统计结果有显著差异.结论: 5-Fu与MMC体外发生协同或相加作用组的联合化疗疗效优于体外发生拮抗作用组.

Correlation Study on in vitro Chemosensitivity of 5-Fu plus Plus MMC with Clinical Response in Human Colorectal Cancers

Objective: To explore correlation in vitro chemosensitivity of 5-Fu plus MMC with clinical response in human colorectal cancers. Method: The chemosensitivity of 5-Fu plus MMC in 96 cases of Dukes B,C colorectal cancer were measured by the MTT method. The incidence of its synergism,additivity, and antagonism were calculated, and the progression-free internal of 36 months following surgery were observed by double-blind method.Result: The inhibition rate of 5-Fu plus MMC was higher than that of single agent,and there were synergism,antagonism,additivity in 5-Fu plus MMC. Among 42 patients using 5-Fu plus MMC, 15 were antagonistic in vitro, and 8 were relapse in 3 years; 27 were synergistic-additive in vitro, and only 5 were relapse in 3 years. The relapse rates of the former were more than the latter with significant difference.Conclusion: The clinical results of 5-Fu plus MMC were better when synergistic-additive in vitro than that of antagonistic.